Skip to main content

Safety, tolerability and efficacy of a rapid dose escalation of quetiapine in bipolar I mania: the FATIMA study

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Constant E, Seghers A, Ranalli E, Ryckmans V, Snauwaert P, Parent M, Vandenhoven G. Safety, tolerability and efficacy of a rapid dose escalation of quetiapine in bipolar I mania: the FATIMA study. Objective:

The FATIMA study (FAst TItration of quetiapine fumarate in bipolar I MAnia) evaluated the safety, tolerability and efficacy of a rapid dose escalation of quetiapine in acutely ill bipolar I patients experiencing a manic episode. Methods:

In an open-label, phase II pilot study, 29 patients aged 18 years or older, hospitalised with a bipolar I manic episode, received quetiapine twice daily for 21 days. Quetiapine was administered at 200, 400, 600, then 800 mg/day on the first 4 days, with flexible dosing (400–800 mg/day) subsequently. The primary endpoint was the proportion of patient dropouts because of adverse drug reactions during the first 7 days. Secondary safety assessments included incidences of adverse drug reactions and significant changes in vital signs. Efficacy assessments included Young Mania Rating Scale (YMRS) and Clinical Global Impressions Severity of Illness (CGI-S) score changes from day 1 to day 21. Results:

Twenty patients (69%) completed the study. No patients withdrew as a result of drug-related adverse events (AEs) during the first 7 days. Twenty-three patients reported 58 adverse events, and most of the adverse events were mild or moderate. No clinically relevant abnormalities in vital signs were reported. Mean YMRS and CGI-S scores decreased significantly from baseline to day 21 (p < 0.001). Response and remission rates were 78 and 70%, respectively, at the end of the study. Conclusion:

Rapid dose escalation of quetiapine to 800 mg/day over 4 days was well tolerated and effective in reducing symptoms within 5 days in acutely ill bipolar I patients with a manic episode.

Keywords: bipolar mania; quetiapine; rapid dose escalation

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1601-5215.2009.00378.x

Affiliations: 1: Cliniques Universitaires Saint-Luc, Bruxelles, Belgium 2: Hôpital Français—César De Paepe asbl, Brussels, Belgium 3: Centre Psychiatrie St Bernard, Manage, Belgium 4: A.Z. Sint-Lucas—Sint Jozef, Assebroek, Belgium 5: Clinique Psychiatrique des Frères Alexiens, Henri-Chapelle, Belgium 6: AstraZeneca Belgium, Brussels, Belgium

Publication date: June 1, 2009

mksg/acn/2009/00000021/00000003/art00005
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more